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Abstract  1 
Background: Cocoa contains polyphenols that are thought to be beneficial to vascular health. 2 
Objective:  We assessed the impact of chocolate containing distinct levels of cocoa on 3 
cerebrovascular function and cognition. Methods:  Using a counterbalanced within-subject 4 
design, we compared the acute impact of consumption of energy-matched chocolate containing 5 
80, 35 and 0% single-origin cacao on vascular endothelial function, cognition and 6 
cerebrovascular function in 12 healthy postmenopausal women (57.3±5.3 yr) who attended a 7 
familiarisation session, followed by 3 experimental trials, separated by 1 week each. Outcome 8 
measures included cerebral blood flow velocity responses, recorded before and during 9 
completion of a computerised cognitive assessment battery (CogState), brachial artery flow-10 
mediated dilation (FMD) and hemodynamic responses (heart rate, blood pressure). Results: 11 
When pre versus post chocolate cerebral blood flow velocity (CBFv) data were compared 12 
between conditions using two-way ANOVA, an interaction effect (P = 0.003), and main effects 13 
for chocolate (P=0.043) and time (P=0.001) were evident. Post hoc analysis revealed that both 14 
milk chocolate (MC; P=0.02) and dark chocolate (DC; P=0.003) induced significantly lower 15 
cerebral blood flow responses during the cognitive tasks, after normalisation for changes in 16 
arterial pressure. DC (80% cocoa) consumption also increased brachial FMD compared with 17 
pre-chocolate baseline (P=0.002), while MC (35%) and white chocolate (WC; 0%) incurred no 18 
change (interaction between conditions P=0.034). Conclusions: Consumption of chocolate 19 
containing high concentrations of cocoa enhanced vascular endothelial function, reflected by 20 
improvements in FMD. Cognitive function outcomes did not differ between conditions, 21 
however cerebral blood flow responses during these cognitive tasks were lower in the MC and 22 
DC conditions. These findings suggest that chocolate containing high concentrations of cacoa 23 
may modify the relationship between cerebral metabolism and blood flow responses in 24 
postmenopausal women. 25 
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Introduction  28 
Chocolate is one of the world’s most consumed foods. In the USA, approximately 5-6 kg of 29 
chocolate is consumed annually, per person (1). Despite this high consumption, chocolate is 30 
sometimes considered to be ‘unhealthy’ and has a reputation for contributing to weight gain 31 
(2) due to the high fat, sugar and caloric content of commercially manufactured products. 32 
However, there is growing evidence that some types of chocolate may provide health benefits 33 
attributable to the high polyphenol content, particularly flavanols, contained within the non-fat 34 
solids of cocoa liquor. These are found in greater concentrations (~5-fold) in dark chocolate 35 
(DC), compared with milk chocolate (MC) (3). By comparison, white chocolate (WC) contains 36 
limited polyphenols as it comprises butter extracted from cocoa liquor and is devoid of non-fat 37 
cocoa solids (4). 38 
 39 
Importantly, flavanols have been associated with antioxidant and anti-inflammatory effects, 40 
along with reductions in platelet reactivity, aggregation and adhesion (5). These actions 41 
promote healthy vascular function (5) and potentially reduce the risk of cardiovascular 42 
mortality (6). Indeed, a number of systematic reviews have concluded that evidence from both 43 
laboratory studies and randomised trials indicate that chocolate and flavanols may confer 44 
cardiovascular benefit (7-10).  Accordingly, some research on the potential health benefits of 45 
chocolate consumption has focussed on endothelial function, assessed via flow-mediated 46 
dilation (FMD). Systematic reviews have suggested that flavanol-rich cocoa and DC produce 47 
significant and favourable effects on brachial artery FMD (8), but this is not a universal finding 48 
(11). However, no studies have adopted a study design involving the acute impact of chocolate 49 
containing distinct concentrations of cocoa, using FMD to assay endothelial function. 50 
 51 
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Whilst enhanced FMD of the brachial artery is indicative of cardiovascular health (12-14), 52 
improvement in cerebrovascular endothelial function may reduce the risk of stroke and enhance 53 
cognitive function (15, 16). Only one previous study, to our knowledge, has assessed 54 
cerebrovascular perfusion in response to a flavanol-rich cocoa-based beverage using 55 
transcranial Doppler (TCD; 17). However, the results of this study are difficult to interpret, due 56 
to the variability in baseline measures, lack of dietary control and the absence of a control 57 
group. There was also no attempt to link cognition and cerebral perfusion. 58 
 59 
The aim of the present study was to assess the acute effect of consuming differing types of 60 
chocolate (80% cocoa “DC”, 35% cocao milk chocolate “MC” and a white chocolate “WC” 61 
containing only cocoa fats) on endothelial and cerebrovascular function in post-menopausal 62 
women. These formulations were manufactured from a single-source and single-batch of cacao 63 
bean and each condition was matched for energy content. We hypothesised that acute 64 
consumption of DC, high in cocoa solids and flavanols, would result in improved vascular 65 
function, including increased brachial artery FMD and cerebrovascular responses to a 66 
standardised cognitive challenge, compared to the consumption of MC. We did not hypothesise 67 
that changes would be apparent in any measures following consumption of WC, in which cocoa 68 
solids are absent. 69 
 70 
 71 
Methods 72 
Participants 73 
Twelve apparently healthy, postmenopausal women (age: 57.3±5.3 yr, weight: 67.3±11.9 kg, 74 
and body mass index: 24.6±4.6 kg.m-2) were recruited from The University of Western 75 
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Australia (UWA) and the local community. Those who smoked, were taking prescribed 76 
medication or had a previous diagnosis of any cardiovascular disease or cognitive disorder 77 
were excluded via a screening questionnaire. Prior to their inclusion in the study, each 78 
participant provided written informed consent and the study was approved by the UWA Human 79 
Research Ethics Committee. 80 
 81 
Study Design and Chocolate Treatment 82 
Using a repeated measures cross-over design, each participant was required to attend four 83 
separate laboratory sessions at the School of Sport Science, Exercise and Health, UWA at the 84 
same time of day. The first visit, a familiarisation session (including baseline assessment of 85 
resting cerebrovascular perfusion and neurovascular coupling with cognitive challenge), was 86 
followed by three experimental trials in which the order of trial administration was 87 
counterbalanced to control for any potential order effect, involving the consumption of (a) high 88 
concentration (80%) cocoa DC, (b) lower concentration (35%) cocoa MC and (c) a WC 89 
containing cocoa fats and no solids. All chocolate treatments were manufactured to our 90 
requirements by an artisanal chocolatier (Gabriel Chocolate Company, Margaret River, 91 
Western Australia) using the same batch of single-origin cacao bean from the Sambirano 92 
Valley, Madagascar, in the desired concentrations of 35% and 80% cocoa, with the WC 93 
condition consisting of the cocoa butter extracted from the same bean. The complete nutritional 94 
composition of each chocolate was analysed by the Australian National Nutritional 95 
Measurement Institute (Melbourne, Vic, 3207, Australia) and is summarised in Table 1. Based 96 
on the nutritional laboratory analysis, we matched the energy content of consumed chocolate 97 
between trials, by feeding participants 85 g of WC, 87 g of MC and 84 g of DC in a 98 
counterbalanced order to provide a total of 2099 kJ under each condition. 99 
 100 
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Familiarisation Session  101 
Participants arrived at the laboratory in the morning after an overnight fast and were given an 102 
overview of the study protocol and requirements before providing informed signed consent. 103 
Participants were instructed to complete a food diary and abstain from caffeine, alcohol, 104 
chocolate and vigorous physical activity during the 24 h prior to each subsequent session. The 105 
food diary required them to record the type, portion size and timing of ingested food and 106 
beverage in detail, for the purpose of being replicated in the 24 h prior to each subsequent 107 
experimental session. This allowed prior energy intake to be matched within-subjects between 108 
trials, with mean total daily energy intake, together with the quantity of carbohydrate, fat, and 109 
protein consumed determined from these records using a commercially available software 110 
program (FoodWorks 7; Xyris Software, Queensland, Australia). 111 
 112 
Body mass and height were recorded and participants were then fitted with a TCD to measure 113 
resting cerebral blood flow velocity (CBFv) for 5 min in the absence of any stimulus, with 114 
their eyes open. Neurovascular coupling of cerebral metabolism and blood flow was assessed 115 
by administering a standardised CogState test (details below) while CBFv was continuously 116 
recorded. Participants were also familiarised with the FMD equipment and procedures. 117 
 118 
Experimental Trials 119 
Participants were then required to visit the laboratory for three experimental testing sessions 120 
conducted over 3 h, on three separate occasions, approximately one week apart. These sessions 121 
were scheduled for the same time of the morning as the familiarisation session, following an 122 
overnight fast and replication of the participants 24 h food diary.  123 
 124 
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After arrival at the laboratory, on each occasion, participants underwent baseline measures of 125 
resting blood pressure, resting CBFv and endothelial function (FMD). The assigned chocolate 126 
treatment was then administered (treatment order was counterbalanced to control for any 127 
potential order effect), with a fixed time of 15 min allowed for consumption. The participants 128 
were blindfolded throughout the consumption phase to prevent visual recognition of the 129 
condition. Chocolate consumption was immediately followed by 30 min of passive rest in a 130 
temperature controlled laboratory environment. Following this, measures of blood pressure, 131 
CBFv and endothelial function were repeated along with the neurovascular coupling 132 
assessment (detailed below). 133 
 134 
Outcome Measures 135 
Assessment of vascular endothelial function 136 
Brachial artery endothelial function was assessed using FMD at baseline and 80 min following 137 
chocolate consumption. Briefly, non-invasive high-resolution ultrasound (Terason, t3200, 138 
Burlington, MA 01803, USA) imaging of the brachial artery was performed on the non-139 
dominant arm, as previously described in our papers. Details of our assessment and analysis 140 
techniques have been published in detail elsewhere (18, 19). 141 
 142 
Assessment of resting cerebrovascular perfusion 143 
CBFv was assessed using TCD (Spencer Technologies, Seattle, WA), described in detail 144 
elsewhere (20). Participants were instrumented with a headframe (Marc 600, Spencer 145 
Technologies) capable of bilaterally transfixing two 2-MHz ultrasound probes over the 146 
temporal window for the duration of both the familiarisation and experimental trials. Bilateral 147 
measures of each middle cerebral artery flow velocities were obtained for 5 min in a rested 148 
state in a standardised room devoid of stimulation. Participants were seated in front of a blank 149 
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whiteboard and told to focus on the screen. Measurements were obtained in this way prior to, 150 
and 60 min after chocolate consumption and exported in real time to a data acquisition system 151 
(PowerLab, LabChart 7; ADInstruments, Sydney, Australia) for post hoc analysis.  152 
 153 
Assessment of neurovascular coupling and cognition 154 
Neurovascular coupling was assessed as the responses of CBFv to increased neural activity 155 
induced by cognitive computer-based tasks (CogState test battery – see below). To minimise 156 
the impact of a learning effect within each trial, responses during these cognitive tasks were 157 
assessed during the familiarisation laboratory visit, which served as baseline data for the 158 
subsequent chocolate consumption experimental trial responses, collected 60 mins after 159 
chocolate consumption. In this way, approximately one week separated each repeat cognitive 160 
task performed in the counterbalanced conditions. 161 
 162 
Cognitive function was assessed using a computer-based cognitive battery (CogState Research 163 
TM), a widely used and accepted academic research tool. In order to familiarise participants 164 
and standardise the administration of the CogState test, written instructions and three to five 165 
practice trials were completed prior to the commencement of each experimental trial, for each 166 
task. The set of assessments chosen for this study were based on other studies investigating the 167 
effect of cocoa ingestion on cognition (21) and included: a detection task assessing 168 
psychomotor function and speed of processing, an identification task assessing visual attention, 169 
the ‘one back’ and ‘two back’ tasks assessing attention and working memory, the ‘international 170 
shopping list learning’ and ‘recall’ tasks assessing verbal learning and memory, and the 171 
continuous paired association learning task assessing visual learning and memory. The stability 172 
and efficiency of the CogState battery for repeated assessment of cognitive function have been 173 
demonstrated (22). 174 
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 175 
Assessment of blood pressure  176 
Beat-to-beat continuous arterial pressure and heart rate traces were recorded for the duration 177 
of all sessions using a Finometer PRO (Finapres Medical Systems, Amsterdam). Blood 178 
pressure and heart rate were continuously assessed with data exported in real time to a data 179 
acquisition system as above. 180 
 181 
Statistical Analysis 182 
Statistical analysis of the data was conducted using SPSS version 20.0 with statistical 183 
significance being accepted at a P < 0.05. The effect of the chocolate conditions on outcome 184 
measures (FMD, resting CBFv and responses to CogState testing), assessed before versus after 185 
consumption, were compared between the experimental conditions using two-way repeated 186 
measures ANOVA [3 x 2 way ANOVA: chocolate type (n=3) vs pre-post time (n=2)]. Changes 187 
in cerebrovascular velocity and conductance were also calculated by subtracting post 188 
administration values from their preceding baselines (see Figure 3). One way ANOVA was 189 
performed on these data.  Post hoc paired t-tests were performed using Least Significant 190 
Difference analysis.  All data are presented as mean±SD unless stated otherwise.  Based on our 191 
published work (19), a sample size of 10 individuals would provide >90% power, assuming 192 
two-tailed alpha=0.05 (G*Power v3.1.2), to detect a change in FMD of 1.4%. A 1% difference 193 
in FMD is associated with clinically meaningful ~7% difference in cardiovascular events (14). 194 
Regarding cerebral measures: given very conservative assumptions, such as a group difference 195 
in volumetric CBFv of 3cms-1 (see Figure 3, WC vs familiarisation), SD=1.5 cms-1 and 196 
alpha=0.01, our study possessed 90% power. 197 
 198 
 199 
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Results 200 
Cerebral blood flow responses before and after chocolate administration 201 
Cerebral blood flow in the middle cerebral artery was successfully achieved in 10 participants; 202 
TCD equipment was unavailable in 1 subject and temporal bone thickness rendered Doppler 203 
signals unattainable in another. Baseline CBFv (pre-chocolate administration) did not differ 204 
between the conditions (P = 0.166; Figure 1A). When CBFv was normalised for mean arterial 205 
pressure (MAP, Figure 1B), cerebrovascular conductance (CVC = CBFv ÷ MAP) baseline 206 
values were similar (P = 0.457; Figure 1C). 207 
 208 
When pre and post chocolate CBFv data were compared between conditions using two-way 209 
ANOVA, an interaction effect (P = 0.003), and main effects for chocolate (P = 0.043) and time 210 
(P  0.001; Figure 1A) were evident.  Subsequent post hoc t-tests revealed no change between 211 
pre and post CBFv following WC administration, however significant decreases following MC 212 
(P = 0.008) and DC (P = 0.001). Similarly, there was a significant interaction (P = 0.014, Figure 213 
1C) and time effect (P = 0.008) between pre and post chocolate CVC data. Subsequent post 214 
hoc t-tests revealed no difference between pre and post CBFv following WC administration (P 215 
= 0.618), however CVC was significantly decreased as a result of MC (P = 0.018) and DC 216 
consumption (P = 0.001). 217 
 218 
Mean arterial pressure and heart rate responses before and after chocolate administration 219 
MAP data for the ten participants that completed the assessment of CBFv before and after 220 
chocolate ingestion are presented in Figure 1B. These data indicate no significant difference in 221 
MAP between conditions at baseline (P = 0.264), and no change in MAP as a result of chocolate 222 
ingestion (conditions P = 0.547; time P = 0.879; interaction P = 0.302). Similarly, there was 223 
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no significant difference in heart rate between conditions at baseline (P = 0.973), and no impact 224 
of chocolate ingestion under any condition (P > 0.05) 225 
 226 
Neurovascular coupling and chocolate administration: Cerebrovascular responses during 227 
cognitive tasking 228 
When chocolate conditions were directly compared, there were no significant differences in 229 
any of the seven CogState measures. Cognitive test performances are shown in Table 2 230 
(available online). 231 
 232 
Cerebrovascular responses (CBFv, MAP and CVC) to the seven measures of cognitive 233 
performance conducted during the no-chocolate familiarisation condition, and 60 min 234 
following chocolate administration of each condition, are presented in figures 2A, 2B and 2C. 235 
These data are summarised in figures 3A and 3B which present change (from the 236 
familiarisation condition) in CBFv and CVC responses during completion of cognitive tasks, 237 
averaged across all 7 measures; analysis performed on these figures therefore assessed the 238 
overall effect of cognitive stimulation on cerebrovascular responses. 239 
 240 
A one-way ANOVA revealed significant differences in CBFv between the conditions in 241 
response to the cognitive tasks (P = 0.001; Figure 3A).  Post hoc t-tests revealed a significant 242 
decrease in CBFv during the cognitive battery following WC (P = 0.029), MC (P = 0.001) and 243 
DC (P < 0.001) ingestion, compared with the no-chocolate familiarisation session. CBFv also 244 
significantly decreased following MC (P = 0.048) and DC (P < 0.001) compared with WC 245 
consumption. 246 
 247 
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After accounting for blood pressure, the change in CVC was also significantly different 248 
between conditions (one-way ANOVA, P = 0.001; Figure 3B). Post hoc t-tests revealed a 249 
significant decrease in CVC during the cognitive battery following MC (P = 0.022) and DC (P 250 
= 0.003), but not WC (P = 0.728), compared with the no-chocolate familiarisation session. 251 
CVC also significantly decreased following MC (P = 0.006) and DC (P = 0.008) compared 252 
with WC consumption. 253 
 254 
Vascular endothelial function: Brachial FMD responses to chocolate administration 255 
FMD was recorded before and 80 min after administration of chocolate in all 12 participants. 256 
There was no difference in baseline (pre-chocolate administration) FMD measures between 257 
conditions (one-way ANOVA; P = 0.158; Figure 4). However, there was a significant 258 
interaction effect (two-way ANOVA; P = 0.034) between pre and post chocolate data between 259 
conditions. Post hoc tests (pre vs post) revealed no differences in FMD following WC or MC, 260 
however a significant increase following DC (P = 0.002). This finding was consistent across 261 
participants, with DC ingestion resulting in a higher FMD% than WC or MC chocolate in nine 262 
of the twelve participants. 263 
 264 
 265 
Discussion 266 
In this study we adopted a cacao concentration-response paradigm, using energy-matched and 267 
custom manufactured chocolate made from single-origin same-batch cacao bean, to examine 268 
impacts on vascular function and cognition in humans using state-of-the-art physiological and 269 
imaging techniques. Flow-mediated dilation (FMD), an endothelium-dependent response 270 
largely mediated by nitric oxide (NO; 23), increased following consumption of chocolate high 271 
in cocoa, but not MC or WC. Interestingly, despite no change in cognitive function across the 272 
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chocolate conditions, cerebral blood flow responses during the cognitive tasks were 273 
significantly lower following consumption of higher cocoa containing chocolate, but not WC. 274 
These findings indicate that consumption of chocolate containing high concentrations of cocoa 275 
can enhance vascular function and increase cerebrovascular efficiency in postmenopausal 276 
women. 277 
 278 
Acute ingestion of DC increased FMD in our study by 2.4%, with no changes observed 279 
following WC or MC. We adopted optimal contemporary approaches to the assessment of 280 
FMD (18), using operator-independent edge detection and wall tracking software (19). An 281 
increase in FMD of this magnitude is potentially associated with clinically significant 282 
reductions in cardiovascular events (12, 13), although the impact of repeated acute treatment 283 
has yet to be established. Our results also correspond with previous acute studies that observed 284 
a 3-4% increase in FMD following DC and a 0-2% decrease following consumption of WC 285 
(24, 25). However, the chocolate consumed under comparator conditions in Faridi et al. was 286 
not matched for energy content (260 kJ difference), while Hermann et al did not disclose the 287 
composition of study comparator chocolate conditions. Neither study assessed a concentration-288 
response of polyphenol consumption. A more recent study observed concentration-dependent 289 
improvements in FMD, pulse wave velocity and blood pressure after treatment with different 290 
concentrations of cocoa powder and flavanols (26). Of interest, it has been reported that a large 291 
proportion (62%) of previous published studies of the impact of chocolate on cardiovascular 292 
endpoints have been industry funded (7). Other previous concentration studies that have 293 
adopted a concentration-response approach have utilised beverages containing cocoa, long 294 
term ingestion, or other approaches that did not involve chocolate administration (27-31).  295 
 296 
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Our study used 3 isocaloric custom-manufactured, single-origin and single-batch cacao bean 297 
conditions (80% cocoa DC, 395 mg flavanols; 35% cocoa MC, 200 mg flavanols; 0% cocoa 298 
WC, 35 mg flavanols). Furthermore, our study is the first to specifically assess acute responses 299 
in postmenopausal women, thereby avoiding the confounding impact, in younger women, of 300 
the menstrual cycle on vascular endothelial responses (32). The improvement in endothelium-301 
mediated vasodilation (FMD) we observed could potentially be due to elevated concentrations 302 
of plasma flavanols, prevalent in higher cocoa containing DC, that have been shown to activate 303 
endothelial NO synthase (eNOS) and increase NO production and bioavailability (33). 304 
 305 
Another major finding relates to cerebral blood flow responses to cognitive demand. Whilst 306 
one previous study has investigated the acute effect of cocoa-based beverage consumption on 307 
cerebrovascular responses using TCD (17), to our knowledge this is the first study to 308 
specifically address the impact of differing cocoa concentrated chocolate on coupling between 309 
cognitive tasks and blood flow. In response to a comprehensive and standardised battery of 310 
tests designed to interrogate distinct cognitive domains (CogState), we observed consistent 311 
decreases in CBFv and conductance responses following ingestion of chocolate containing 312 
higher levels of cocoa. No such changes were observed following ingestion of WC. These 313 
results somewhat contradict those of Sorond et al., who observed no change in cerebrovascular 314 
reactivity following acute consumption of a commercial cocoa beverage in elderly individuals 315 
(17). This disparity may relate to the different populations studied in each trial, or to 316 
methodological differences, as Sorond et al. did not include different concentrations of cocoa, 317 
or a control condition. In contrast, our 3 experimental chocolate conditions were matched for 318 
energy intake and principally differed by virtue of cocoa content, and hence flavanol 319 
concentration. 320 
 321 
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The decreases in CBF we observed in response to chocolate consumption persisted after 322 
normalisation for concurrent blood pressure change, so cannot be attributed to an impact on 323 
systemic hemodynamics. We also did not observe significant differences in cognitive 324 
performance, despite the blood flow requirement to sustain such performance being 325 
significantly diminished. These findings infer sustained performance in the face of diminished 326 
blood flow and, hence, oxygen delivery. Interestingly, Francis et al performed a study in which 327 
daily flavanol-rich cocoa consumption over 5 days increased blood oxygenation in active brain 328 
regions, assessed by fMRI, in the absence of any change in cognitive performance (34). These 329 
findings, and our FMD data in the current study, lead us to speculate that flavanol-mediated 330 
NO production in the presence of higher cocoa concentrated chocolate (33), may modify 331 
cerebral metabolism and consequently decrease oxygen demand in active brain regions. Further 332 
studies will be required to address this proposition pertaining to “neurovascular efficiency”. 333 
 334 
In terms of cognition, the current results conflict with those of Field et al. who found that DC 335 
acutely increased cognitive performance in domains similar to our visual attention and visual 336 
memory tasks, compared with WC in young adults (35). Like other studies, these researchers 337 
did not assess concentration-responses in regards to polyphenol consumption and used 338 
commercially available chocolate, likely made from differing cacao beans each containing 339 
distinct polyphenol breakdown. Another study of older individuals (mean 52 yr), which utilised 340 
differing concentrations of flavanols (0, 250 or 500 mg) in the form of commercial cocoa 341 
beverages consumed over 30 days (36), observed no effect on performance of a cognitive task 342 
similar to our visual memory task. This is consistent with our findings, across multiple 343 
CogState task domains (speed of processing, verbal memory and verbal memory recall). Our 344 
findings that differing cocoa concentrated chocolate did not modify cognitive performance is 345 
therefore broadly consistent with the extant literature. 346 
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 347 
This study possesses several strengths and some limitations. It is the first, to our knowledge, to 348 
strictly control the type, composition and energy content of the chocolate used, which we had 349 
specifically manufactured to our purpose of utilising a concentration-response approach, with 350 
conditions counterbalanced and blinded to the participant. The use of a single-origin cacao 351 
bean ensured the constituents, in particular flavonoid breakdown (catechin, epicatechin and 352 
proanthocyanidin concentrations) were consistent between conditions. All chocolate 353 
conditions were energy matched (2099 kJ) as participants consumed either 85 g of WC, 87 g 354 
of MC or 84 g of DC, in a counterbalanced order to control for any potential order effect. 355 
Additionally, participants were fasted the morning of testing and instructed to avoid caffeine, 356 
chocolate, alcohol and intense physical activity in the 24 h prior to experimental assessments. 357 
The completion and replication of a food diary allowed the 24 h prior to experimental testing 358 
to be assessed and this was similar between conditions. The techniques we adopted to assess 359 
peripheral and cerebral vascular responses are well validated and accepted in the literature (18, 360 
20) and our approaches are state-of-the-art and largely operator independent (18, 19). We also 361 
adopted a standardised and well accepted psychometric tool (CogState) that provided 362 
information on a range of cognitive domains, after a thorough familiarisation. Although the 363 
chocolate we utilised was specifically manufactured and supplied for this study by an artisanal 364 
chocolatier, the product was purchased at the full commercial cost and no conflicts of interest 365 
existed in our study. The limitations of this study include the relatively small sample size, 366 
although our concentration-response findings are internally consistent (dark>milk>white) and 367 
the findings were statistically significant. Finally, it is an accepted limitation of the use of 368 
transcranial Doppler that diameter measures are not derived, and that velocity is used as a 369 
surrogate for flow (and in the calculation of conductance).  Future research should focus on 370 
additional measurements including MRI-based CBF and arterial diameter measures. 371 
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 372 
In conclusion, this study suggests that higher concentrations of cocoa in chocolate induce 373 
favourable effects on endothelial function and neurovascular efficiency. Such effects may 374 
conceivably relate to the impact of flavanols on endothelial function and NO bioavailability, 375 
in both the peripheral and cerebral vasculature. If confirmed and extended in the context of 376 
chronic administration, our findings may have implications for arterial health in 377 
postmenopausal women at risk of cardiovascular disease, stroke and cognitive decline. 378 
 379 
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Figure 1. Impacts of chocolate containing different concentrations of cocoa on cerebral 
blood flow velocity and blood pressure at rest.  A) Resting middle cerebral artery 
velocity (cm.s-1), before and after consumption of white, milk and dark chocolate (WC, 
MC and DC respectively). B) Resting mean arterial pressure (mm Hg) before and after 
consumption of WC, MC and DC. C) Resting cerebrovascular conductance (cm.s-1 mm 
Hg-1), before and after consumption of WC, MC and DC. (n = 10; mean ± SE). * † ‡ 
Indicates significant difference from pre-chocolate consumption within condition (*P 
< 0.05; †P < 0.01; ‡P < 0.005).  
 
Figure 2. Impacts of chocolate containing different concentrations of cocoa on cerebral 
blood flow velocity and blood pressure in response to individual cognitive tasks.  
A) Change (ie post-rest) in middle cerebral artery velocity (cm.s-1) after consumption 
of white, milk and dark chocolate (WC, MC and DC respectively) or non-chocolate 
familiarisation during seven cognitive tasks B) Mean arterial pressure (mm Hg) at 
familiarisation (no chocolate treatment) and following consumption of WC, MC and 
DC during seven cognitive tasks C) Change in cerebrovascular conductance (cm-1 mm 
Hg-1) following consumption of WC, MC and DC or non-chocolate familiarisation 
during seven cognitive tasks. (n = 10; mean ± SE). * † ‡ Indicates significant difference 
from familiarisation (*P < 0.05; †P < 0.01; ‡P < 0.005).  
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Figure 3. Impacts of chocolate containing different concentrations of cocoa on average 
cerebral blood flow velocity in response to all cognitive tasks. A) Change (ie post-
rest) in middle cerebral artery velocity (cm.s-1), following consumption of white, milk 
and dark chocolate (WC, MC and DC respectively) or a non-chocolate familiarisation, 
across the seven cognitive tests in Figure 2. B) Similarly calculated change in 
cerebrovascular conductance (cm-1 mm Hg-1), as middle cerebral artery velocity 
normalised for blood pressure (n = 10; mean ± SE). * † ‡ Indicates significant difference 
from familiarisation (*P < 0.05; †P < 0.01; ‡P < 0.005). 
 
Figure 4. Impacts of chocolate containing different concentrations of cocoa on brachial 
artery flow-mediated dilation. Flow-mediated dilation (%) of the brachial artery 
before and 80 min after chocolate consumption of white, milk and dark chocolate (WC, 
MC and DC respectively); n = 12; mean ± SE). ‡ Indicates significant difference from 
pre-chocolate consumption within trial (‡P < 0.005). 
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Table 1. Composition of different chocolate conditions 
Nutritional components  White chocolate 
(WC) 
Milk chocolate 
(MC; 35% 
cocoa) 
Dark chocolate 
(DC; 80% 
cocoa) 
Energy (kJ/100 g)  2470 2420 2490 
Amount consumed (g) 85 87 84 
Energy consumed (kJ) 2099 2099 2099 
Carbohydrates (g)  44.2 42.6 36.1 
Total sugars (g) 42.5 35.7 19.3 
Fat (g)  34.1 34.0 36.3 
Saturated fat (g)  21.3 21.1 22.1 
Mono-unsaturated fats (g)  9.9 10.2 11.4 
Poly-unsaturated fat (g) 1.1 1.0 1.0 
Protein (g)  4.9 7.1 7.8 
Total polyphenols (mg) 34.9 200.1 394.8 
Total Flavonoids (mg/kg) 370 980 3600 
Epicatechin (µg/g) Not detected  288.4 587.1 
Catechin (µg/g) 38.4 770.1 1394.2 
 
